Garraud Olivier
EA3064 University of Lyon, Faculty of Medicine of Saint-Etienne, 42023 Saint-Etienne Cedex 02, France; Institut National de la Transfusion Sanguine, 75015 Paris, France.
Transfus Apher Sci. 2017 Feb;56(1):31-34. doi: 10.1016/j.transci.2016.12.014. Epub 2016 Dec 30.
The recent Ebola virus epidemics which threatened three West African countries (Dec.2014-Apr.2016) has urged global collaborative health organizations and countries to set up measures to stop the infection and to treat patients, near half of them being at risk of death. Convalescent plasma-recovered from rescued West Africans-was considered a feasible therapeutic option. Efficacy was difficult to evaluate because of numerous unknowns (especially evolution of neutralizing antibodies), prior to the cessation of active transmission. This raises a large body of questions spanning epidemiological, virological, immunological but also ethical, sociological and anthropological aspects, alongside with public health concerns, in order to be better prepared to the next outbreak. This essay summarizes efforts made by a large number of groups worldwide, and attempts to address still unanswered questions on the benefit of specific versus non-specific plasma on altered-leaking-vascular endothelia in Ebola infection.
近期在三个西非国家爆发的埃博拉病毒疫情（2014年12月至2016年4月）促使全球合作卫生组织及各国采取措施阻止感染并治疗患者，其中近半数患者面临死亡风险。从获救的西非人体内采集的康复期血浆被视为一种可行的治疗选择。在病毒的主动传播停止之前，由于存在众多未知因素（尤其是中和抗体的演变情况），疗效难以评估。这引发了一系列涵盖流行病学、病毒学、免疫学，以及伦理、社会学和人类学等方面的问题，同时也涉及公共卫生问题，以便为应对下一次疫情做好更充分的准备。本文总结了全球众多团队所做的努力，并试图解决关于在埃博拉感染中，特异性血浆与非特异性血浆对血管内皮渗漏改变的益处方面仍未得到解答的问题。
